Penghui Zhou

12PUBLICATIONS
41CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Major global burdens of diseaseProteomics and intermolecular interactions (excl. medical proteomics)Innate immunityPsychopharmacology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 16, 2026
Author Correction: Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.

|Mar 03, 2026
GITR activation potentiates anti-tumor immunity of tumor-infiltrating lymphocytes expanded from glioblastoma by rescuing exhaustion.

Jiayi Zhou, Yinggui Yang, Ran Ye

|Jun 18, 2025
R9AP is a common receptor for EBV infection in epithelial cells and B cells.

Yan Li, Hua Zhang, Cong Sun

|Nov 02, 2024
Publisher Correction: Cytoplasmic FBXO38 mediates PD-1 degradation.

Xiwei Liu, Xiangbo Meng, Zuomiao Lin

|Sep 30, 2024
Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity.

Zining Wang, Lei Cui, Yanxun Lin

|Sep 18, 2024
Cytoplasmic FBXO38 mediates PD-1 degradation.

Xiwei Liu, Xiangbo Meng, Zuomiao Lin

Pageof 2

Frequent Collaborators

3 joint publications

Tiebang Kang

2 joint publications

Limin Zheng

2 joint publications

Yuanzhong Wu

2 joint publications

Shao-Cong Sun